Inhibition of lncRNA DCST1‐AS1 suppresses proliferation, migration and invasion of cervical cancer cells by increasing miR‐874‐3p expression

Abstract

BackgroundCervical cancer seriously threatens both the health and life of women. We aimed to investigate whether RNA interference of long non‐coding RNA (lncRNA) DCST1‐AS1 could promote miR‐874‐3p expression to affect the proliferation, migration and invasion of cervical cancer cells.MethodsDCST1‐AS1 expression levels in cervical cancer cells and transfection effects were detected by quantitative reverse transcriptase‐polymerase chain reaction analysis. Proliferation, invasion and migration of cells were separately shown by cell‐counting kit‐8, wound healing and transwell assays, and relative protein expression was determined by western blot analysis. Dual‐luciferase reporter and RNA immunoprecipitation assays verified the interaction of DCST1‐AS1 and miR‐874‐3p.ResultsDCST1‐AS1 expression was increased in cervical cancer tissues and cells. The DCST1‐AS1 expression in Hela and SiHa cells was the highest, and so the cells were selected for the next experiment. Inhibition of DCST1‐AS1 suppressed the proliferation, invasion and migration of cervical cancer cells and decreased the expression of KI67, proliferating cell nuclear antigen, matrix metalloproteinase (MMP)‐2 and MMP‐9. miR‐874‐3p expression was increased when cells were transfected with miR‐874‐3p mimic or shRNA‐DCST1‐AS1‐1, and DCST1‐AS1 expression was down‐regulated when cells were transfected with miR‐874‐3p mimic. DCST1‐AS1 can directly target miR‐874‐3p. Furthermore, inhibition of miR‐874‐3p could effectively alleviate the effect of inhibition of DCST1‐AS1 with respect to the proliferation, invasion and migration of cervical cancer cells.ConclusionsInhibition of DCST1‐AS1 suppressed the proliferation, migration and invasion of cervical cancer cells by increasing miR‐874‐3p expression, which could be alleviated by the inhibition of miR‐874‐3p.

RETRACTED ARTICLE: Long non-coding RNA DCST1-AS1/hsa-miR-582-5p/HMGB1 axis regulates colorectal cancer progression

“…LncRNA DCST1-AS1 is suggested to play an oncogenic role in cancer initiation and development. For example, lncRNA DCST1-AS1 promotes the development of cervical cancer (CC) [ 41 ], cervical squamous cell carcinoma [ 42 ], endometrial carcinoma [ 43 ], gastric cancer [ 44 ], Triple-negative breast cancer [ 18 ] and hepatocellular carcinoma [ 17 ] by targeting miRNAs. In our study, we found that the lncRNA DCST1-AS1 is upregulated in CRC tumor tissues, and patients with high level of lncRNA DCST1-AS1 is associated with a poor prognosis.…”

LncRNA DCST1-AS1 Promotes Endometrial Cancer Progression by Modulating the MiR-665/HOXB5 and MiR-873-5p/CADM1 Pathways

“…LncRNA DC-STAMP domain-containing 1-antisense 1 (DCST1-AS1) was overexpressed in various tumor types, including breast cancer, glioblastoma, cervical cancer, and hepatocellular carcinoma (16)(17)(18)(19). Elevated expression of DCST1-AS1 regulates cancer progression by sponging different miRNAs and influencing the downstream signaling pathways (16)(17)(18)(19). However, our current understanding of DCST1-AS1 in EC is still limited.…”

miR-874: An Important Regulator in Human Diseases

“…As shown in Table 1 , miR-874 is downregulated in at least 22 human malignancies, such as colorectal cancer (CRC) ( Huang et al, 2020a ; Yu et al, 2020 ; Que et al, 2017 ; Zhao and Dong, 2016 ; Han et al, 2016 ; Wang et al, 2021 ; Zhang et al, 2021c ), gastric cancer (GC) ( Huang et al, 2018 ; Sun et al, 2020 ; Yuan et al, 2020 ; Liu et al, 2017 ; Zhang et al, 2015 ; Jiang et al, 2014 ), hepatocellular carcinoma (HCC) ( Zhang et al, 2018b ; Jiang et al, 2017 ; Leong et al, 2017 ; Song et al, 2016 ), esophageal squamous cell carcinoma (ESCC) ( Yuan et al, 2018 ), pancreatic ductal adenocarcinoma (PDAC) ( Diao et al, 2018 ), non-small cell lung cancer (NSCLC) ( Bu et al, 2020 ; Yang et al, 2017 ; Ahmad et al, 2015 ; Kesanakurti et al, 2013 ; Wang et al, 2020b ), osteosarcoma (OS) ( Tang et al, 2018 ; Liu et al, 2020 ; Dong et al, 2016 ; Ghosh et al, 2017 ), epithelial ovarian cancer (EOC) ( Xia et al, 2018 ) cervical cancer (CC) ( Liao et al, 2018 ; Liu et al, 2021a ), retinoblastoma (RB) ( Zhang et al, 2018a ; Wang et al, 2020a ), prostate cancer (PCa) ( Pashaei et al, 2017 ) maxillary sinus squamous cell carcinoma (MSCC) ( Nohata et al, 2011 ), breast cancer (BC) ( Li et al, 2020 ; Zhang et al, 2017 ; Wang et al, 2014 ), triple-negative breast cancer (TNBC) ( Wu et al, 2020 ), rhabdomyosarcoma (RMS) ( Shang et al, 2019 ), papillary thyroid carcinoma (PTC) ( Ding et al, 2021 ), endometrial cancer ( Witek et al, 2021 ), cholangiocarcinoma ( Pan et al, 2021 ), glioma ( Li et al, 2021a ), myeloma (MM) ( Tian et al, 2021 ), head and neck squamous cell carcinoma (HNSCC) ( Nohata et al, 2013 ) and acute myeloid leukemia (AML) ( Zhang et al, 2021a ).…”

“…In OS, the downregulated lncRNA XLOC_008466/miR-874-3p/CCNE1 axis can also inhibit tumor growth ( Ghosh et al, 2017 ). The expression of lncRNA DCST1-AS1 increases in cervical cancer tissues and cells, and inhibition of DCST1-AS1 can increase the expression of miR-874-3p, thereby inhibiting the proliferation, migration and invasion of cervical cancer cells ( Liu et al, 2021a ). In PTC, miR-874-3p can inhibit FAM84A and exert carcinogenic effects through the Wnt/β-catenin signal transduction ( Ding et al, 2021 ).…”